UNITAID Stakeholders Briefing

21 July 2015

Vancouver, Canada

Accelerating Innovation for Pediatric ARV Formulations: Review of Progress of Mutual Accountability Framework

This stakeholder briefing took place at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. The briefing included updates from the Paediatric Treatment Initiative and the Global Pediatric ARV Commitment-to‐Action.

DNDi’s Head of Paediatric HIV Programme, Marc Lallemant, took part in a high-level panel discussion on overcoming challenges and advancing opportunities to accelerate product innovation and market uptake of new pediatric ARV formulations.

Panel

Accelerating Innovation for Pediatric ARV Formulations

Date: July 21, 2015

Moderated by: Dr Robert Hecht, Managing Director, Results for Development Institute

Ambassador Deborah Birx, U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy, U.S. Department of State
Dr Gottfried Hirnschall, Director, Department of HIV and Global Hepatitis Programme, World Health Organization
Mr Martin Auton, Senior Specialist, Lead for the Sourcing of HIV Products, Global Fund
Mr Fernando Pascual, PHTI Interim Coordinator
Mr Robert Matiru, Director, Operations a.i., UNITAID
Dr Marc Lallemant, Head Paediatric HIV Program, DNDi
Dr David Ripin, Executive Vice President, Access, and Chief Scientific Officer, CHAI
Dr Manuel Gonçalves, Vice President, External Affairs and Communications, ViiV Healthcare
Mr Bhavesh Shah, Vice President - International Marketing at Hetero Drugs Ltd